Welcome to BioSeeker Group!

BioSeeker Cancer Highlights™ Publications

A Decision Support Tool for Optimizing the Cancer Pipeline Portfolio. From Research and Development to Market.

Cancer Highlights™ is BioSeeker Group’s flagship decision support tool, for portfolio assessment and planning of cancer drug development.


Drug development is not what it used to be. Gone are the days of relying on blockbusters. Instead, the drug industry is faced with identifying incremental drug improvements towards personalized medicine that will be commercially compelling. Tremendous opportunities in the field of personalized medicine are the new horizon.

Cancer Highlights™ is written for you to understand and assess the impact of competitors and the corresponding changes to development strategies in oncology for your own portfolio products. It helps business teams to maximize molecule value by selecting optimal development plans and managing risk and uncertainty.

Watch our Cancer Highlights™ Presentation Video


Drug target strategies are the critical link between drugs and their role in the treatment of medical disorders. Cancer Highlights™ applies systems to attain robust analytical and strategic insight to support both internally to pipeline and portfolio planning and to stakeholders across your own organization. It will also be an important part of creating and implementing a market development plan for cancer drugs to ensure that the optimal market conditions exist by the time the product is commercialized.

We deliver these insights to you through our Cancer Focus Areas.

Cancer Focus Areas

The Cancer Highlights™ publication range examines 14 different, high impact Cancer Focus Areas, divided into the three main classes of Tumor Type, Mechanism/Target/Effect and Compound Strategy.



Cancer Highlights’™ Five Pillar Assessment

Cancer Highlights™ uses standardized criteria in a five pillar assessment to compare drug development strategies in oncology, making it easy to find and compare analysis not only within one single Cancer Focus Area but also between different areas.
These five pillars are:

  • I - Considering the Therapeutic Target
  • II - Emerging New Products to Established Ones
  • III - Compound Strategies at Work
  • IV - Selecting Cancer Indications
  • V - Pipeline & Portfolio Planning


Click here to request more information and free sample pages from the Cancer Highlights series.

Subscribe Today and Start Saving

We at BioSeeker would like to invite you to maximize your commercial insights in oncology to an optimized budget. Our competitively priced Cancer Highlights™ is an attractive investment for many companies, from big pharma to emerging biotechnology companies. You will save 65-75% compared to a normal single copy price.

A subscription consists of eight (8) consecutive reports from a rolling update of 14 different Cancer Focus Areas. Your subscription will commence with the latest report available and automatically end after eight (8) publications and you will be notified about making a renewal. BioSeeker publishes new reports every six weeks and these will be immediately delivered to your inbox in PDF format.


Click here to start your Cancer Highlights Subscription


Key Benefits

Cancer Highlights™ serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning in oncology by:

• Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
• Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties
• Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
• Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
• Supporting development of integrative molecule, pathway and disease area strategies
• Integrating knowledge to help you to consider the therapeutic target for the highest therapeutic outcome and return on investment

Available Cancer Highlights Reports

When you purchase a single issue of Cancer Highlights, you may subtract your first investment from the subscription price when you upgrade to a subscription, within a month from the date of purchase.

List of reports...

64 Item(s)

per page

Set Ascending Direction
  1. Vascular Targeting Agents: Emerging Competitors

    $1,950.00
    Published by BioSeeker Group on Feb 8th, 2005
    An update on the most recent advances made for vascular targeting agents that are now entering an exciting stage of development. Learn More

  2. Therapeutic Peptides in Oncology - Favorable Conditions But Where to Commercialize?

    $2,450.00
    Published by BioSeeker Group on May 28th, 2009
    This report is an important part of creating and implementing a market development plan for any cancer therapeutic peptide drugs to ensure that the optimal market conditions exist by the time the product is commercialized. Learn More

  3. The Global Competitive Landscape of Antibody Drug Development in Cancer: The Faster Route to Consider Your Options and Position of Others

    $2,450.00
    Published by BioSeeker Group on Sep 27th, 2011
    This report will excel your competitive awareness and decrease your decision making time in one of the fastest growing segments in the pharmaceutical market, namely antibodies for the treatment of cancer. Learn More

  4. The Drug Target Atlas of Protein Kinase Inhibitors in Oncology

    $2,450.00
    Published by BioSeeker Group on Nov 5th, 2007
    This report is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of new protein kinase inhibitor drugs in oncology. Learn More

  5. The Drug Target Atlas of Apoptotic Drugs in Oncology

    $2,450.00
    Published by BioSeeker Group on Feb 6th, 2008
    First in place, BioSeeker has surveyed apoptopic drugs in oncology and identified 119 drug targets, belonging to 114 drugs. This report, The Drug Target Atlas of Apoptopic Drugs in Oncology, is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of new apoptopic drugs in oncology. Learn More

  6. The Deployment of Antibody Technologies for the Advancement of Cancer Therapeutics

    $2,300.00
    Published by BioSeeker Group on Apr 1st, 2008
    The discovery of new cancer therapeutics has seen a significant shift towards biologicals as an alternative to small molecule drugs. Targeted biologics utilizing monoclonal antibody-based technologies have rapidly developed into one of the major market segments of the pharmaceutical industry. Learn More

  7. The Commercial Success of Cancer Therapeutic Antibodies - The Formation of a Second Wave

    $1,950.00
    Published by BioSeeker Group on Nov 22nd, 2005
    The blockbuster drugs Rituxan, Avastin, and Erbitux have change the way the industry looks upon antibody treatment of cancer in the same way that Taxol changed the way pharmaceutical companies look at the possibilities in the field of cancer therapeutics. Learn More

  8. Targeted Therapeutics in Non-Small Cell Lung Cancer

    $1,950.00
    Published by BioSeeker Group on Apr 26th, 2007
    With this report you will be able to track down and foresee activities associated with the development of new treatments for NSCLC. Learn More

  9. Target Atlas: Competitive Insights to Anti-Angiogenic Drug R&D in Oncology

    $2,450.00
    Published by BioSeeker Group on Mar 17th, 2008
    This report is written for you to identify your competition and understand which targeting strategies are at work within anti-angiogenic drug development in oncology. It allows you to pin-point which competitors drugs’ clinical out-come may have bearing on your own drug development and who are developing sequels to blockbuster drugs. This report also helps you to locate white-spots in the competitive landscape, giving you little or no competition. Conversly it may reveal unexpected competition for you. Learn More

  10. Superficial Bladder Cancer - Current Mangement and Future Trends

    $1,290.00
    Published by BioSeeker Group on Nov 1st, 2005
    Superficial bladder cancers (SBC) comprise tumours with low aggressiveness but a high recurrence rate as well as lesions with a high risk of progression. Learn More

  11. Strategic Outlook on Protein Kinase Inhibitors in Oncology

    $1,950.00
    Published by BioSeeker Group on Feb 20th, 2006
    A strategic outlook on protein kinase inhibitors in oncology. Including targets, indictions and competitive assessment. Learn More

  12. Protein Kinase Therapeutics in Oncology - Where to Commercialize?

    $2,450.00
    Published by BioSeeker Group on Oct 29th, 2009
    This report is an important part of creating and implementing a market development plan for any protein kinase drug in oncology to ensure that the optimal market conditions exist by the time the product is commercialized. Learn More

  13. Prostate Cancer - A Therapeutic & Competitive Insight

    $1,950.00
    Published by BioSeeker Group on Jan 5th, 2007
    In this report BioSeeker does not only describe and analyze the latest years of progress but as well provide an insight and framework to understand the complex field of prostate cancer therapeutics. Learn More

  14. Portfolio Analytics in the Pancreatic Cancer Pipeline and Portfolio Planning - High Unmet Medical Need but Where to Target?

    $1,950.00
    Published by BioSeeker Group on Mar 23rd, 2010
    The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in pancreatic cancer. Learn More

  15. Portfolio Analytics and Planning in the Breast Cancer Pipeline - Change is Around the Corner in a Highly Competitive Market Place

    $1,950.00
    Published by BioSeeker Group on Apr 26th, 2010
    This report comprises defined and up to date development strategies for 405 breast cancer drugs within the portfolio of 220 investigators, from Ceased to Marketed. The report extensively analyses 207 identified targets of breast cancer drugs, organized into 193 drug target strategies, and assesses them in breast cancer. Significantly new breast cancer therapies will soon come to challenge old established drugs on the market. Learn More

  16. New Concepts in Cancer Therapeutics

    $2,450.00
    Published by BioSeeker Group on Dec 30th, 2005
    There are, at present, ten times more anticancer drugs being tested in clinical trials than there were 20 years ago. Many of the new classes of agents.... Learn More

  17. Melanoma Therapeutics: Which Strategy Will Take Us There?

    $2,450.00
    Published by BioSeeker Group on Jul 18th, 2005
    Melanoma drug development has and will continue to have a strong focus on target therapy such as vaccines, monoclonal antibodies, dendritic cells, and gene therapy. Learn More

  18. Melanoma Drug Development Analysis: From First-in-Class to Best-in-Class?

    Regular Price: $1,950.00

    Special Price: $975.00

    Published by BioSeeker Group on Jun 12th, 2013
    In-depth pipeline analytics of melanoma drugs showing you where the competition is, what is first-in-class and is first-in-class the best-in-class?, indication expansion opportunities and much more Learn More

  19. Melanoma - Targeted Therapeutics

    $1,950.00
    Published by BioSeeker Group on Jul 19th, 2007
    This in-depth analysis of the progress of melanoma R&D and current treatment strategies is one of the most extensive reports available in this field. Learn More

  20. Lymphoma Drug Development Strategies at Work - Define Your Competition

    $1,950.00
    Published by BioSeeker Group on Jun 22nd, 2009
    This report will be an important part of creating and implementing a market development plan for any lymphoma therapeutic drug to ensure that the optimal market conditions exist by the time the product is commercialized. Learn More

  21. Lymphoma - A Therapeutic & Competitive Insight

    $1,950.00
    Published by BioSeeker Group on May 29th, 2006
    Gain insight into the current challenges and commercial opportunities associated with lymphoma therapy Learn More

  22. Lung Cancer: A Decision Support Tool for Optimizing the Pipeline from Research To Market

    Regular Price: $1,950.00

    Special Price: $975.00

    Published by BioSeeker Group on Jul 12th, 2011
    This report comprises defined and up to date development strategies for 416 lung cancer drugs within the portfolio of 217 companies, from Ceased to Marketed. The report extensively analyses their 241 identified drug targets, organized into 237 drug target strategies, and assesses them in eight different compound strategies and three subindications of lung cancer. Learn More

  23. Leukemia - A Therapeutic & Competitive Insight

    $1,950.00
    Published by BioSeeker Group on Oct 6th, 2006
    In the report "Leukemia - A Therapeutic & Competitive Insight" BioSeeker does not only describe and analyze the latest years of progress in four different market segments; CLL, CML ALL and AML, but also provide an insight and framework to understand the complex field of leukemia therapeutics. Learn More

  24. Leukemia - A Competitive Analysis to New Products, Portfolio Planning, Licensing & Acquisition Through Pipeline Benchmarking

    $1,950.00
    Published by BioSeeker Group on Apr 3rd, 2009
    The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio of leukemia products. Learn More

  25. Large Pharma:2004 a year of Progress

    $1,950.00
    Published by BioSeeker Group on Jan 18th, 2005
    BioSeeker Group analyzes the progress made by the large pharmaceutical companies top oncology drug candidates whom has reached Phase III clinical evaluation. Learn More

  26. Global Pipeline Review & Analysis of Hematological Malignancies

    $2,450.00
    Published by BioSeeker Group on Mar 27th, 2007
    In this unique report the hematological cancer pipeline is analyzed and cross referenced by: Investigator,Drug, Sub-indication, Developmental stage, Compound type, Targeted therapy strategy, Target, and Signaling pathway. Learn More

  27. Global Cancer Focus Company Directory

    $1,950.00
    Published by BioSeeker Group on Apr 30th, 2007
    Global Cancer Focus Company Directory pulls out virtually all cancer drug developing companies in the world. After several acquisitions and mergers in the market place, BioSeeker offers you the tool to get an updated look on the competitive landscape in oncology, including almost 900 hundred companies in 39 different countries. Learn More

  28. Decoding Big Pharmas R&D Strategy in Oncology

    $2,450.00
    Published by BioSeeker Group on Sep 14th, 2007
    This report, Decoding Big Pharma’s R&D Strategy in Oncology, is based on five major pharmaceutical companies in the oncology arena: Bristol-Myers Squibb, GlaxoSmithKline, Hoffmann-La Roche, and Sanofi-Aventis. Learn More

  29. Currently Druggable in Prostate Cancer: A Drug Target Competitive Analysis

    $1,950.00
    Published by BioSeeker Group on Sep 8th, 2008
    This report is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of prostate cancer drugs. Learn More

  30. Currently Druggable in Melanoma: A Drug Target Competitive Analysis

    $1,950.00
    Published by BioSeeker Group on Oct 14th, 2008
    This report is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of melanoma drugs. Learn More

  31. Currently Druggable in Colorectal Cancer: A Drug Target Competitive Analysis

    $1,950.00
    Published by BioSeeker Group on Dec 19th, 2008
    This report is an open landscape of resources to build, fuel, and drive your scientific competitive vehicle for the advancement of colorectal cancer drugs. Learn More

  32. Currently Druggable in Breast Cancer: A Drug Target Competitive Analysis

    $1,950.00
    Published by BioSeeker Group on Aug 12th, 2008
    This report aims to analyze the current and future potential of breast cancer pipeline by examining key fundamentals across the entire pipeline of drug candidates. BioSeeker has identified three fundamental dimensions to outline the competitive landscape within the pharmaceutical industry; compound type, therapy area and target type. Learn More

  33. Current and Future Therapies for Lung Cancer - A Therapeutic and Competitive Insight

    $1,950.00
    Published by BioSeeker Group on Mar 14th, 2006
    With this report you will be able to track down and foresee activities associated with the development of new treatments for lung cancer. Learn More

  34. Current and Future Therapies for Colorectal Cancer - A Therapeutic & Competitive Insight

    $1,950.00
    Published by BioSeeker Group on Sep 19th, 2005
    Colorectal cancer (CRC) is the second most common cause of cancer death in much of the developed world. Cancer-related mortality is slowly decreasing as a result of better detection and significant advances in the treatment of advanced colorectal cancer over the past 5 years. Learn More

  35. Competitive Outlook on Non-Antibody Based Cancer Vaccines

    $1,950.00
    Published by BioSeeker Group on Aug 3rd, 2006
    Research and development in the cancer vaccine field is dominated by its top 10 players, interestingly not including any of the big pharma companies per se. The recent Gardasil approval and GlaxoSmithKline’s acquisition of Corixa will certainly push the industry towards more acquisitions. With this in mind, this report makes an in-depth assessment of competitive landscape, tumor antigen technologies, immunostimulatory strategies, vaccine delivery technologies, and a progress analysis of six major cancer vaccine indications. Learn More

  36. Competitive Outlook on Lung Cancer Drug Development - The Missing Handbook to New Product Planning and Portfolio Planning

    $2,450.00
    Published by BioSeeker Group on Aug 25th, 2009
    This report is an important part of creating and implementing a market development plan for any lung cancer therapeutic drugs to ensure that the optimal market conditions exist by the time the product is commercialized. Learn More

  37. Competitive Outlook on Apoptosis in Oncology

    $1,950.00
    Published by BioSeeker Group on Dec 19th, 2006
    Cancer cells frequently and possibly invariably possess apoptotic defects. In this context, apoptotic pathways provide exciting molecular targets for new therapeutic agents to specifically promote apoptosis of cancer cells. Learn More

  38. Competitive Outlook on Antiangiogenesis and Vascular Targeting in Oncology

    $1,950.00
    Published by BioSeeker Group on Oct 9th, 2006
    Assess opportunities and risks for the continued development of anti-angiogenic and vascular targeting agents in five major cancer indications. Learn More

  39. Competitive Insights to Protein Kinase Therapeutics in Oncology: The Faster Route to Consider Your Options and Position of Others

    Regular Price: $2,950.00

    Special Price: $1,475.00

    Published by BioSeeker Group on May 1st, 2012
    This report represents a new and unique way of stratifying and analyzing the global protein kinase drug pipeline in oncology towards personalized medicine. Learn More

  40. Competitive Handbook towards Personalized Medicine in Prostate Cancer

    Regular Price: $1,950.00

    Special Price: $975.00

    Published by BioSeeker Group on Sep 12th, 2012
    This report is a new and unique way of stratifying and analyzing the global prostate cancer pipeline towards personalized medicine and presents actionable analysis Learn More

  41. Commercializing Peptides in Oncology: A Decision Support Tool for Optimizing the Pipeline

    $2,450.00
    Published by BioSeeker Group on Jun 24th, 2010
    This report identifies the competitive terrain for cancer therapeutic peptides to be wide open from a compound perspective and the opportunity for peptide drugs to challenge other biologicals such as antibodies is real and significant. Learn More

  42. Commercializing Peptides in Cancer: The Faster Route to Consider Your Options and Position of Others

    $2,450.00
    Published by BioSeeker Group on Nov 14th, 2011
    This report will excel your competitive awareness and decrease your decision making time in managing peptide drug development in cancer. Learn More

  43. Commercializing Pancreatic Cancer Drugs: The Faster Route to Consider Your Options and Position of Others

    Regular Price: $1,950.00

    Special Price: $975.00

    Published by BioSeeker Group on Mar 1st, 2012
    This report comprises defined and up to date development strategies for 247 pancreatic cancer drugs within the portfolio of 158 companies world-wide, from Ceased to Marketed. The report extensively analyses their 197 identified drug targets, organized into 163 drug target strategies, and assesses them in pancreatic cancer. Learn More

  44. Commercializing Cancer Vaccines: A Decision Support Tool for Optimizing the Pipeline

    $1,950.00
    Published by BioSeeker Group on Oct 14th, 2010
    This report comprises defined and up to date development strategies for 155 cancer vaccine drugs within the portfolio of 99 investigators, from Ceased to Marketed. The report extensively analyses their 94 identified drug targets, organized into 91 drug target strategies, and assesses them in 42 different cancer indications. Learn More

  45. Commercializing Cancer Drugs Affecting Angiogenesis: A Decision Support Tool for Optimizing the Pipeline

    $2,450.00
    Published by BioSeeker Group on Sep 7th, 2010
    This report comprises defined and up to date development strategies for 239 angiogenesis affecting drugs in oncology within the portfolio of 148 corporate investigators, from Ceased to Marketed. The report extensively analyses their 174 identified drug targets, organized into 167 drug target strategies, and assesses them in 64 different cancer indications. Learn More

  46. Commercializing Breast Cancer Drugs: The Faster Route to Consider Your Options and Position of Others

    Regular Price: $1,950.00

    Special Price: $975.00

    Published by BioSeeker Group on Aug 1st, 2012
    This report represents a new and unique way of stratifying and analyzing the global breast cancer drug pipeline towards personalized medicine. Learn More

  47. Commercializing Apoptotic Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

    Regular Price: $2,450.00

    Special Price: $1,225.00

    Published by BioSeeker Group on Dec 19th, 2011
    This report will excel your competitive awareness and decrease your decision making time in managing apoptotic drug development in cancer. Find out whether you are number one, two or further down the ladder in this highly competitive market. Locate the right drugs to benchmark against and see were others may have succeeded or failed before you. Learn More

  48. Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

    Regular Price: $2,450.00

    Special Price: $1,225.00

    Published by BioSeeker Group on Jan 30th, 2012
    This report comprises defined and up to date development strategies for 252 angiogenesis affecting drugs in oncology within the portfolio of 151 companies world-wide, from Ceased to Marketed. The report extensively analyses their 177 identified drug targets, organized into 170 drug target strategies, and assesses them in 70 cancer indications. Learn More

  49. Cancer Vaccines: From First-in-Class to Best-in-Class?

    Regular Price: $1,950.00

    Special Price: $975.00

    Published by BioSeeker Group on Mar 19th, 2013
    In-depth pipeline analytics of cancer vaccine drugs showing you where the competition is, what is first-in-class and is first-in-class the best-in-class?, Indication expansion opportunities and much more Learn More

  50. Cancer Vaccines: Aim and Shoot

    $1,950.00
    Published by BioSeeker Group on May 19th, 2008
    This report aims to analyze the current and future potential of cancer vaccines by examining key fundamentals across the entire pipeline of cancer vaccine drug candidates. Learn More

  51. Cancer Vaccines Fantasy or Future?

    $1,950.00
    Published by BioSeeker Group on Feb 1st, 2005
    In this newly updated progress analysis, BioSeeker not only provide a solid background and information structure, we also bring the latest within cancer vaccine achievements. Learn More

  52. Cancer Peptides: From First-in-Class to Best-in-Class?

    Regular Price: $2,450.00

    Special Price: $1,225.00

    Published by BioSeeker Group on Jan 7th, 2013
    In-depth pipeline analytics of peptide drugs in oncology showing you where the Competition is, What is first-in-class and Is First-in-Class the Best-in-Class?, Indication expansion opportunities and much more Learn More

  53. Cancer Antibodies: Drug Target Atlas and Competitive Outlook

    Regular Price: $2,450.00

    Special Price: $1,225.00

    Published by BioSeeker Group on Nov 1st, 2012
    This report is a new and unique way of stratifying and analyzing the global antibody pipeline in cancer towards personalized medicine and presents actionable analysis Learn More

  54. Cancer Antibodies: Competitive Positioning for Success

    $1,950.00
    Published by BioSeeker Group on Jun 3rd, 2008
    This report is written for you to identify your competition and understand which targeting strategies are at work within antibody drug development. It allows you to pin-point which competitors drugs’ clinical out-come may have bearing on your own drug development and who are developing sequels to blockbuster drugs. This report also helps you to locate white-spots in the competitive landscape, giving you little or no competition. Conversely it may reveal unexpected competition for you. Learn More

  55. Breast Cancer - Therapeutic And Competitive Insights

    $1,950.00
    Published by BioSeeker Group on Feb 28th, 2007
    Gain insight into the current challenges and commercial opportunities associated with breast cancer therapy. Learn More

  56. Apoptotic Therapeutics in Oncology - Where to Commercialize?

    $2,450.00
    Published by BioSeeker Group on Nov 30th, 2009
    The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It serves as an external commercial advocate for pharmaceutical companies’ portfolio planning and new product planning. Learn More

  57. Apoptosis: Promise or deception?

    $1,950.00
    Published by BioSeeker Group on May 7th, 2005
    In this publication, BioSeeker Group analyzes the latest progress made for 25 drug candidates targeting the cell death pathway, apoptosis. Additionally, more early stage candidates are also under investigation, which brings the total number of companies interested in this field to around 40. Learn More

  58. Antibody Drug Target Atlas in Oncology - Where to Commercialize in a Crowded Market Place?

    $2,450.00
    Published by BioSeeker Group on Mar 1st, 2010
    This report comprises defined and up to date development strategies for 441 antibody drugs (993 projects) within the portfolio of 168 investigators, from Ceased to Marketed. The report extensively analyses 225 identified targets of antibody drugs, organized into 234 drug target profiles, and assesses them in 69 different cancer indications. Learn More

  59. Antibody Drug Target Atlas in Oncology

    $2,450.00
    Published by BioSeeker Group on Jun 12th, 2007
    First of its kind, "Antibody Drug Target Atlas in Oncology" provides a comprehensive analysis of the commercialization of antibody drug targets in oncology Learn More

  60. A Decision Support Tool for Optimizing the Prostate Cancer Pipeline: From Research and Development to Market

    $1,950.00
    Published by BioSeeker Group on May 24th, 2010
    This report comprises defined and up to date development strategies for 346 prostate cancer drugs within the portfolio of 198 investigators, from Ceased to Marketed. The report extensively analyses 202 identified targets of prostate cancer drugs, organized into 187 drug target strategies, and assesses them in prostate cancer. Significantly new prostate cancer therapies will soon come to challenge old established drugs on the market. Four out of five target strategies in Phase III and nine out of ten in Phase II are novel and innovative in their design. Learn More

  61. A Decision Support Tool for Optimizing the Melanoma Pipeline: From Research and Development to Market

    $1,950.00
    Published by BioSeeker Group on Nov 17th, 2010
    This report comprises defined and up to date development strategies for 218 melanoma drugs within the portfolio of 138 companies, from Ceased to Marketed. The report extensively analyses their 170 identified drug targets, organized into 151 drug target strategies, and assesses them in eight different compound strategies in melanoma. Learn More

  62. A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market

    Regular Price: $1,950.00

    Special Price: $975.00

    Published by BioSeeker Group on May 18th, 2011
    This report comprises defined and up to date development strategies for 282 lymphoma drugs within the portfolio of 152 companies, from Ceased to Marketed. The report extensively analyses their 181 identified drug targets, organized into 173 drug target strategies, and assesses them in eight different compound strategies and five subindications of lymphoma. Learn More

  63. A Decision Support Tool for Optimizing The Leukemia Pipeline: From Research and Development to Market

    Regular Price: $1,950.00

    Special Price: $975.00

    Published by BioSeeker Group on Apr 25th, 2011
    This report comprises defined and up to date development strategies for 313 leukemia drugs within the portfolio of 186 companies, from Ceased to Marketed. The report extensively analyses their 204 identified drug targets, organized into 193 drug target strategies, and assesses them in eight different compound strategies and eight subindications of leukemia. Learn More

  64. A Decision Support Tool for Optimizing The Colorectal Cancer Pipeline: From Research and Development to Market

    Regular Price: $1,950.00

    Special Price: $975.00

    Published by BioSeeker Group on Mar 7th, 2011
    The colorectal cancer report part comprises defined and up to date development strategies for 347 colorectal cancer drugs within the portfolio of 182 investigators, from Ceased to Marketed. This part extensively analyses their 210 identified drug targets, organized into 205 drug target strategies, and assesses them in eight different compound strategies in colorectal cancer. Learn More

64 Item(s)

per page

Set Ascending Direction